CA2759873A1 - Influenza hemagglutinin compositions and uses thereof - Google Patents

Influenza hemagglutinin compositions and uses thereof Download PDF

Info

Publication number
CA2759873A1
CA2759873A1 CA2759873A CA2759873A CA2759873A1 CA 2759873 A1 CA2759873 A1 CA 2759873A1 CA 2759873 A CA2759873 A CA 2759873A CA 2759873 A CA2759873 A CA 2759873A CA 2759873 A1 CA2759873 A1 CA 2759873A1
Authority
CA
Canada
Prior art keywords
ectodomain
influenza
seq
amino acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2759873A
Other languages
English (en)
French (fr)
Inventor
Martin Bachmann
Andrea Jegerlehner
Philippe Saudan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of CA2759873A1 publication Critical patent/CA2759873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2759873A 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof Abandoned CA2759873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159262.6 2009-04-30
EP09159262 2009-04-30
PCT/EP2010/055944 WO2010125202A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA2759873A1 true CA2759873A1 (en) 2010-11-04

Family

ID=42790940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759873A Abandoned CA2759873A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Country Status (9)

Country Link
US (1) US20120263743A1 (enExample)
EP (1) EP2424570A1 (enExample)
JP (1) JP2012525134A (enExample)
CN (1) CN102573915B (enExample)
AU (1) AU2010243490A1 (enExample)
CA (1) CA2759873A1 (enExample)
NZ (1) NZ596058A (enExample)
SG (1) SG175382A1 (enExample)
WO (1) WO2010125202A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
MA55313A (fr) * 2019-03-13 2022-01-19 Generation Bio Co Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781396B2 (en) * 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP2196217A1 (en) * 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CN100509057C (zh) * 2001-11-07 2009-07-08 赛托斯生物技术公司 用于治疗骨病的抗原阵列
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
KR20060031607A (ko) * 2003-07-10 2006-04-12 사이토스 바이오테크놀로지 아게 패킹된 바이러스-양 입자
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
JP2008513035A (ja) * 2004-09-21 2008-05-01 サイトス バイオテクノロジー アーゲー Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子
WO2007011904A2 (en) * 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
CN101605558A (zh) * 2005-08-16 2009-12-16 夏威夷生物技术公司 流感重组亚单位疫苗
JP5714799B2 (ja) * 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
CA2638760A1 (en) * 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof

Also Published As

Publication number Publication date
WO2010125202A1 (en) 2010-11-04
US20120263743A1 (en) 2012-10-18
EP2424570A1 (en) 2012-03-07
NZ596058A (en) 2013-08-30
AU2010243490A1 (en) 2011-11-24
CN102573915B (zh) 2015-02-18
SG175382A1 (en) 2011-12-29
CN102573915A (zh) 2012-07-11
JP2012525134A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
US20220305131A1 (en) Modified virus-like particles of cmv
RU2540871C2 (ru) Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
AU2006224529B2 (en) Cat allergen fusion proteins and uses thereof
CN103957891B (zh) 基于流感血凝素蛋白的新颖疫苗
EP1603590A2 (en) Influenza virus vaccine
Park et al. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
WO2016087863A1 (en) Vaccines based on hepatitis b core antigens
AU2017256727B2 (en) Treatment of canine atopic dermatitis
US10898569B2 (en) Treatment of peanut allergy
US20120263743A1 (en) Influenza hemagglutinin compositions and uses thereof
WO2010122164A1 (en) VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
WO2025073874A1 (en) Vaccine composition comprising m2e nanoparticles and ha1 protein
HK40077650A (en) Modified virus-like particles of cmv
STRODS Hepatitis B core protein and Bacteriophage AP205 and GA coat protein formed virus-like particles for packaging and addressing
BR122024008858B1 (pt) Uso de uma composição farmacêutica compreendendo uma partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e um antígeno no tratamento de uma doença, distúrbio ou condição em um animal ou ser humano
HK1255670B (zh) Cmv的修饰病毒样颗粒

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160502